PD‐L1 expression in patients with non‐small‐cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population

Abstract Background Programmed cell death‐ligand 1 (PD‐L1) expression is a well‐established biomarker for predicting responses to immune checkpoint inhibitors and certain targeted therapies. As a result, treatment strategies for patients vary based on their PD‐L1 expression status. Understanding the...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	P. Sarova, B. Mosleh, S. Zehetmayer, F. Oberndorfer, J. Widder, H. Prosch, C. Aigner, M. Idzko, M. A. Hoda, D. Gompelmann
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-07-01
Reeks:	Thoracic Cancer
Onderwerpen:	gender medicine genetic aberrations non‐small cell lung cancer PD‐L1 status
Online toegang:	https://doi.org/10.1111/1759-7714.15336
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!